Phase 2 DAHLIA study in SjogrensAnti-neonatal Fc receptor an “nipocalimab” w/remarkably encouraging resultsclinE
Tweet Content
Phase 2 DAHLIA study in Sjogrens Anti-neonatal Fc receptor an “nipocalimab” w/remarkably encouraging results clinESSDAI significantly better at wk24, notably met QOL domains as well Finally getting good news in SjS! #ACR24 @RheumNow #ACRbest Abst#2527 https://t.co/e3uQmqJZ1o
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
On